
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is fundamentally supported by Cabometyx’s durable commercial franchise, which produced $604.9M in sales out of $658.7M in 3Q26 revenue, while diluted net earnings of $0.85 per share and ~$1.4B in cash, cash equivalents, and marketable securities show strong current profitability and balance-sheet flexibility. Its longer-term outlook is strengthened by a pipeline led by zanzalintinib, which is in six pivotal programs and could diversify growth beyond Cabometyx as generics are expected to begin eroding the franchise in 2031, with management also reinvesting cash into broader precision-oncology opportunities. Near-term catalysts such as the 1Q27 STELLAR-304 readout and potential March 3, 2027 FDA approval for zanzalintinib plus atezolizumab, combined with the company’s ability to fund development without additional equity financing, underpin the positive fundamental view.
Bears say
Exelixis is viewed negatively because Cabometyx, the company’s core profit driver, faces an approaching patent cliff and likely market-share erosion in RCC as new regimens and 505(b)(2) copycats intensify pricing pressure. At the same time, management’s next growth engine, zanzalintinib, is still too early to offset Cabometyx’s slowing organic volume growth, and its value is highly concentrated at about two-thirds of operating value, making any regulatory or clinical disappointment especially damaging. If Cabometyx also fails to gain meaningful traction in NETs or HCC, the company’s revenue base and earnings power could compress sharply, leaving the stock vulnerable to volatility and downside.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Exelixis (EXEL) Forecast
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares